Vinge advises Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with its sale of stake in its social infrastructure portfolio for public education to Brookfield for SEK 9.2 billion. The transaction also includes earn out payments up to SEK 1.2 billion.
The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed unsecured loan facility of up to EUR 30 million. The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company, inter alia, satisfies certain milestones related to the ongoing commercialization of Pepaxti® in Europe and a potential relaunch of Pepaxto® in the US. In connection with the loan agreement, Oncopeptides has entered into a renewed warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.
Aneo Renewables Holding AS has made a public mandatory bid for all shares in Scandinavian Biogas Fuels International AB. The offer values the shares of Scandinavian Biogas at approximately SEK 670 million. Vinge advises Aneo.
Scandinavian Biogas Fuels International AB has carried out a directed share issue of SEK 326 million. Vinge advised Aneo Renewables Holding AS (Scandinavian Biogas’ largest shareholder).
Vinge has advised Re:NewCell, a textile-to-textile recycling company listed on Nasdaq First North Premier Growth Market, in connection with a directed share issue whereby the company raised proceeds of approximately SEK 158 million before issue costs.
Vinge has advised Azelio AB (publ) on a fully guaranteed rights issue, which will provide Azelio with issue proceeds amounting to approximately SEK 300 million before deduction of transaction costs.
Vinge has advised Xspray Pharma, a pharmaceutical company with several product candidates in clinical development listed on Nasdaq Stockholm, in connection with a share issue whereby the company raises proceeds of SEK 100 million.
Vinge has advised Nordea Bank Abp, filial i Sverige, Corporate Finance in connection with the rendering of a fairness opinion regarding Karo Intressenter’s public offer to the shareholders of Karo Pharma AB.
Vinge has advised Semcon AB (publ) in connection with a public takeover offer provided by Etteplan Oyj to the shareholders of Semcon. The offer prices SEK 149 per share and values Semcon AB approximately SEK 2 699.
Vinge has advised the founders Rikard Virta, Linus Wennerström and Johan Oscarsson as well as the other shareholders in conjunction with the sale of Future Media Group AB to Caybon.
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 435,6 million, before issue costs. The price per share in the share issue corresponds to the closing price on Nasdaq Stockholm the day of the share issue.
Vinge has advised Studentbostäder i Norden in connection with a directed share issue whereby the company receives SEK 125 million in issue proceeds before deduction of transaction costs.
